Literature DB >> 1515454

Cleavage of type VIII collagen by human neutrophil elastase.

R Kittelberger1, T J Neale, K T Francky, N S Greenhill, G J Gibson.   

Abstract

In this report, the susceptibility of type VIII collagen to human neutrophil elastase is compared to other extracellular matrix components. Type X collagen is degraded to specific fragments at a substrate to enzyme ratio of 5:1 after 20 h at room temperature, but type VIII collagen is almost completely degraded after only 4 h incubation at a substrate to enzyme ratio of 50:1 and partly degraded after only 15 min. Laminin, merosin and types I, III, IV and V collagen exhibit no susceptibility to neutrophil elastase under the latter conditions, while fibronectin is degraded.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515454     DOI: 10.1016/0925-4439(92)90103-t

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancer.

Authors:  Nicholas Willumsen; Lars Nannestad Jorgensen; Morten Asser Karsdal
Journal:  Cancer Biol Ther       Date:  2019-01-09       Impact factor: 4.742

2.  Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide.

Authors:  Jean-Pierre Lévesque; Jean Hendy; Yasushi Takamatsu; Paul J Simmons; Linda J Bendall
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

3.  Lesional elastase activity in psoriasis. Diagnostic and prognostic significance.

Authors:  O Wiedow; F Wiese; E Christophers
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

4.  Upregulation of distinct collagen transcripts in post-surgery scar tissue: a study of conjunctival fibrosis.

Authors:  Li-Fong Seet; Li Zhen Toh; Stephanie W L Chu; Sharon N Finger; Jocelyn L L Chua; Tina T Wong
Journal:  Dis Model Mech       Date:  2017-03-22       Impact factor: 5.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.